- Reported net sales totaled $1.4
billion, essentially flat year-over-year. Sales grew 1.4 percent in
constant currency.
- GAAP earnings from continuing
operations were $0.29 per diluted share.
- Adjusted earnings1
from continuing operations totaled $0.58 per diluted
share.
- Company narrows range of fiscal 2017
adjusted earnings1 guidance from continuing
operations.
Patterson Companies, Inc. (Nasdaq: PDCO) today reported
consolidated net sales of $1.4 billion (see attached Sales Summary
for further details) in its fiscal third quarter ended January 28,
2017, down 0.2 percent over the same period last year. Adjusting
for the effects of currency translation, sales improved 1.4
percent.
Reported net income from continuing operations was $27.8
million, or $0.29 per diluted share, compared to $57.2 million, or
$0.60 per diluted share, in last year’s fiscal third quarter.
Adjusted net income1 from continuing operations, which excludes
certain non-recurring and deal amortization costs, totaled $55.4
million for the third quarter of fiscal 2017, down 14.9 percent
from $65.1 million in the same quarter last year. Adjusted net
income1 from continuing operations includes the previously
disclosed pre-tax step-up in enterprise resource planning expenses,
which for the quarter totaled approximately $11 million. Adjusted
earnings per diluted share1 from continuing operations totaled
$0.58 in the 2017 third quarter, down 14.7 percent
year-over-year.
“Our performance in the fiscal 2017 third quarter reflects our
ongoing efforts to adapt and capitalize in end markets that
continue to present both challenges and opportunities,” said Scott
Anderson, chairman, president and chief executive officer. “Market
conditions in our respective business segments were similar to the
first half of our fiscal year. Our Dental strategy to better serve
the full range of customers with a wider core equipment product
portfolio, delivered and supported at a higher level of value,
yielded positive results. In our Animal Health segment, we explored
and began to implement initiatives to better convert our sales
execution into margin improvement. The long-term trends in our end
markets remain promising, and we are confident that our present
efforts will help us leverage the growth opportunities ahead.”
Patterson DentalReported net sales in our Dental segment,
which represented approximately 45 percent of total company sales,
were $626.3 million, down 1.8 percent from the same quarter last
year. Sales declined 2.0 percent on a constant currency basis from
the fiscal 2016 third quarter. On that same basis, year-over-year
sales by category were as follows:
- Consumable dental supplies decreased
2.8 percent
- Equipment sales declined 1.0 percent,
reflecting strong performance in core equipment, offset by weaker
performance in technology products
- Other services and products, primarily
composed of technical service, parts and labor, software support
services and office supplies, decreased 1.3 percent
Anderson continued, “Consumable sales during the quarter
reflected similar market conditions experienced in the first half
of our fiscal year. However, we are encouraged by core equipment
sales in the third quarter and believe the improvement in this
category validates our experience and success with broadening our
product offerings to achieve future growth, while also increasing
sales with longstanding partners. Through expanding our product
portfolio and enhancing our sales productivity and sophistication,
we are better positioning Patterson Dental to serve a wider range
of customers and clinical environments.”
As disclosed in the fiscal 2017 second quarter, during the
fiscal 2017 third quarter Patterson Companies recorded a pre-tax
non-cash impairment charge of $36.3 million, or $23.0 million after
taxes or $0.24 per diluted share, related to the distribution fee
associated with the CEREC product component of our relationship
with Sirona Dental Systems. While this non-cash accounting charge
will not affect Patterson’s liquidity, cash flows or compliance
with its debt covenants, the company expects this decision to
negatively affect near-term operations.
Patterson Animal HealthReported net sales for Patterson
Animal Health, which comprised approximately 55 percent of the
company’s total sales, were $762.6 million, 1.7 percent higher than
last year. Sales increased 4.9 percent on a constant currency basis
from the fiscal 2016 third quarter. On that same basis,
year-over-year sales by category were as follows:
- Companion animal sales improved 8.5
percent
- Production animal sales rose 1.3
percent, reflecting strong sales in swine, offset by lower sales in
beef- and dairy-cattle categories
“We continued to face margin pressure with certain
pharmaceutical products in our Animal Health segment during the
third quarter, however, we identified and began to implement
approaches to adapt our sales and marketing strategies to achieve
more profitable growth,” added Anderson. “While our work on this
front continues, we began to see some improvement late in the third
quarter. We believe these efforts, in combination with our scale,
commitment to sales execution, and long history of collaboration
with product manufacturers, will help pave the way to margin
improvement.”
Discontinued OperationsOn August 28, 2015, Patterson
Companies completed the sale of Patterson Medical to Madison
Dearborn Partners for approximately $717 million. As a result of
the sale, Patterson Medical is classified and reported as
discontinued operations for all periods presented.
Share Repurchases and DividendsFiscal year-to-date,
Patterson repurchased approximately 2.0 million shares of its
outstanding common stock, with a value of $86.9 million, leaving
approximately 14.5 million shares for repurchase under the current
authorization, which expires in March 2018. The company also paid
$23.3 million in cash dividends to shareholders in the third
quarter and $70.9 million in cash dividends to shareholders in the
first nine months of fiscal 2017.
Year-to-Date Results1Reported net sales for the
first nine months of fiscal 2017 totaled $4.1 billion, a 5.5
percent year-over-year increase. Adjusting for the effects of
currency translation, sales increased 7.3 percent. Sales improved
8.8 percent in constant currency when accounting for the extra week
in the prior nine-month period. Reported net income from continuing
operations was $112.4 million, or $1.17 per diluted share, compared
to $120.1 million, or $1.22 per diluted share in last year’s
period. Adjusted net income from continuing operations1, which
excludes certain non-recurring and deal amortization costs and tax
costs related to tax repatriation, totaled $157.7 million,
or $1.64 per diluted share, compared to adjusted net
income from continuing operations of $167.3 million,
or $1.70 per diluted share, in the year-ago period. Sales
in the prior year nine-month period included an extra sales week
and approximately six fewer weeks of contribution from Animal
Health International, Inc.
Business OutlookAnderson concluded, “Patterson Companies
is evolving its businesses on multiple fronts in response to market
dynamics for improved, long-term top- and bottom-line growth. In
Dental, we are taking the important steps necessary to further
increase our relevancy and value to all practice environments. In
Animal Health, we are approximately halfway through our three-year
integration timeframe. We are combining synergy progress with our
current efforts to improve profitability to enhance the long-term
performance in this segment. While these combined efforts will take
time to fully realize their impact, they are critical to driving
the full potential of the platform we have built.”
Fiscal 2017 GuidanceWith one quarter remaining in fiscal
2017, Patterson today narrowed its fiscal 2017 earnings guidance
from continuing operations, which is provided on both a GAAP and
non-GAAP adjusted1 basis:
- GAAP earnings are now expected to be in
the range of $1.71 to $1.77 per diluted share.
- Non-GAAP adjusted earnings1 are now
expected to be in the range of $2.27 to $2.33 per diluted
share.
- Our non-GAAP adjusted earnings1
guidance excludes the after-tax impact of:
- Deal amortization expense of
approximately $27 million ($0.28 per diluted share)
- Non-cash impairment charges of
approximately $23 million ($0.24 per diluted share)
- Integration and business restructuring
expenses of approximately $5 million ($0.05 per diluted share)
- Transaction-related costs of
approximately $2 million ($0.02 per diluted share)
- Benefit from cash repatriation tax
adjustment of approximately $2 million ($0.03 per diluted
share)
Our guidance is for current continuing operations as well as
completed or previously announced acquisitions and does not include
the impact of potential future acquisitions or similar
transactions, if any, or impairments and material restructurings
beyond those previously publicly disclosed. Our guidance assumes
North American and international market conditions similar to those
experienced in the first nine months of fiscal 2017, and includes
the previously disclosed pre-tax $25 million step-up in operating
expense associated with the enterprise resource planning system
implementation.
1Non-GAAP Financial Measures
The Reconciliation of GAAP to non-GAAP Measures table appearing
behind the accompanying financial information is provided to adjust
reported GAAP measures, namely earnings from continuing operations,
net income from continuing operations, and earnings per diluted
share from continuing operations, for the impact of transaction
related costs, deal amortization, integration and business
restructuring expenses, accelerated debt issuance costs and tax
impact of cash repatriation.
Management believes that these non-GAAP measures may provide a
helpful representation of the company’s current quarter
performance, and enable comparison of financial results between
periods where certain items may vary independent of business
performance. These non-GAAP financial measures are presented
solely for informational and comparative purposes and should not be
regarded as a replacement for corresponding, similarly captioned,
GAAP measures.
In addition, the term constant currency used in this release
represents net sales adjusted to exclude foreign currency impacts.
Foreign currency impact represents the difference in results that
is attributable to fluctuations in currency exchange rates the
company uses to convert results for all foreign entities where the
functional currency is not the U.S. dollar. The company calculates
the impact as the difference between the current period results
translated using the current period currency exchange rates and
using the comparable prior period’s currency exchange rates. The
company believes the disclosure of net sales changes in constant
currency provides useful supplementary information to investors in
light of significant fluctuations in currency rates.
Third-Quarter Conference Call and ReplayPatterson’s
third-quarter earnings conference call will start at 10 a.m.
Eastern today. Investors can listen to a live webcast of the
conference call at www.pattersoncompanies.com. The conference call
will be archived on Patterson’s website. A replay of the fiscal
2017 third quarter conference call can be heard for one week at
888-203-1112 and by providing the Conference ID 7051341 when
prompted.
About Patterson Companies, Inc.Patterson Companies, Inc.
is a value-added distributor serving the dental and animal health
markets.
Dental MarketPatterson's Dental
segment provides a virtually complete range of consumable dental
products, equipment and software, turnkey digital solutions and
value-added services to dentists and dental laboratories throughout
North America.
Animal Health MarketPatterson's
Animal Health segment is a leading distributor of products,
services and technologies to both the production and companion
animal health markets in North America and the U.K.
This press release contains certain forward-looking statements,
as defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are information of a non-historical
nature and are subject to risks and uncertainties that are beyond
Patterson's ability to control. Forward-looking statements
generally can be identified by words such as "believes," "expects,"
"anticipates," "foresees," "forecasts," "estimates" or other words
or phrases of similar import. It is uncertain whether any of the
events anticipated by the forward-looking statements will transpire
or occur, or if any of them do, what impact they will have on the
results of operations and financial condition of Patterson or the
price of Patterson stock. These forward-looking statements involve
certain risks and uncertainties that could cause actual results to
differ materially from those indicated in such forward-looking
statements, including but not limited to the other risks and
important factors contained and identified in Patterson's filings
with the Securities and Exchange Commission, such as its Quarterly
Reports on Form 10-Q and Annual Reports on Form 10-K, any of which
could cause actual results to differ materially from the
forward-looking statements. Any forward-looking statement in this
press release speaks only as of the date on which it is made.
Except to the extent required under the federal securities laws,
Patterson does not intend to update or revise the forward-looking
statements.
Source: Patterson Companies, Inc.
PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED
STATEMENTS OF INCOME (In thousands, except per share
amounts) (Unaudited)
Three Months Ended Nine Months
Ended January 28, January 30, January 28,
January 30, 2017 2016 2017 2016
Net sales $ 1,397,418 $ 1,400,853 $ 4,148,095 $ 3,932,933
Gross profit 329,761 339,864 965,899 959,007
Operating expenses 283,207 244,135
774,126 717,638 Operating income
from continuing operations 46,554 95,729 191,773 241,369
Other income and expense: Other income, net 994 830 4,980 2,454
Interest expense (11,400 ) (10,634 ) (31,659 )
(39,931 ) Income from continuing operations before
taxes 36,148 85,925 165,094 203,892 Income tax expense
8,379 28,735 52,663
83,828 Net income from continuing operations
27,769 57,190 112,431 120,064 Net income (loss) from discontinued
operations (3,229 ) (750 ) (3,229 )
1,500 Net income $ 24,540 $ 56,440 $ 109,202
$ 121,564 Basic earnings (loss) per share:
Continuing operations $ 0.29 $ 0.60 $ 1.18 $ 1.23 Discontinued
operations (0.03 ) (0.01 ) (0.03 ) 0.01
Net basic earnings per share $ 0.26 $ 0.59 $
1.15 $ 1.24 Diluted earnings (loss) per share:
Continuing operations $ 0.29 $ 0.60 $ 1.17 $ 1.22 Discontinued
operations (0.03 ) (0.01 ) (0.03 ) 0.01
Net diluted earnings per share $ 0.26 $ 0.59 $
1.14 $ 1.23 Shares: Basic 94,737 95,335 95,252
97,809 Diluted 95,359 95,930 95,915 98,488 Dividends
declared per common share $ 0.24 $ 0.22 $ 0.72 $ 0.66
PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED BALANCE
SHEETS (In thousands)
January 28,
April
30,
2017 2016 (Unaudited) ASSETS Current
assets: Cash and cash equivalents $ 121,739 $ 137,453 Receivables
810,155 796,693 Inventory 827,057 722,140 Prepaid expenses and
other current assets 112,265 91,255 Total current
assets 1,871,216 1,747,541 Property and equipment, net 300,395
293,315 Goodwill and other intangible assets 1,247,480 1,325,889
Long-term receivables, net and other 174,971 154,059
Total assets $ 3,594,062 $ 3,520,804
LIABILITIES AND
STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $
547,662 $ 566,253 Other accrued liabilities 228,037 226,582 Current
maturities of long-term debt 14,754 16,500 Borrowings on revolving
credit 198,000 20,000 Total current liabilities
988,453 829,335 Long-term debt 1,001,775 1,022,155 Other
non-current liabilities 217,759 227,568 Total
liabilities 2,207,987 2,079,058 Stockholders' equity
1,386,075 1,441,746 Total liabilities and stockholders'
equity $ 3,594,062 $ 3,520,804
PATTERSON
COMPANIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS (In thousands) (Unaudited)
Nine Months Ended January
28, January 30, 2017 2016
Operating activities: Net income $ 109,202 $ 121,564 Net
income (loss) from discontinued operations (3,229 )
1,500 Net income from continuing operations 112,431 120,064
Adjustments to reconcile net income from continuing operations to
net cash used in operating activities: Depreciation and
amortization 63,056 58,817 Intangible asset impairment 36,312 —
Non-cash employee compensation 17,254 20,587 Change in assets and
liabilities, net of acquired (238,464 ) (247,015 )
Net cash used in operating activities- continuing operations (9,411
) (47,547 ) Net cash used in operating activities- discontinued
operations (3,229 ) (38,985 ) Net cash used in
operating activities (12,640 ) (86,532 )
Investing
activities: Additions to property and equipment (37,457 )
(56,280 ) Acquisitions and equity investments, net of cash assumed
— (1,106,583 ) Proceeds from sale of securities — 48,744 Other
investing activities 35,869 — Net cash
used in investing activities- continuing operations (1,588 )
(1,114,119 ) Net cash provided by investing activities-
discontinued operations — 714,680 Net
cash used in investing activities (1,588 ) (399,439 )
Financing
activities: Dividends paid (70,947 ) (67,010 ) Repurchases of
common stock (84,651 ) (200,000 ) Proceeds from issuance of
long-term debt, net — 988,400 Debt amendment costs (1,266 ) —
Retirement of long-term debt (22,550 ) (678,250 ) Draw on revolver
178,000 198,000 Other financing activities 5,495
5,523 Net cash provided by financing activities 4,081
246,663 Effect of exchange rate changes on cash (5,567 )
(10,251 ) Net change in cash and cash equivalents $ (15,714
) $ (249,559 )
PATTERSON COMPANIES, INC.
SALES SUMMARY (Dollars in thousands)
(Unaudited)
Total Foreign
Animal Health January 28, January 30,
Sales
Exchange
International
Internal
2017 2016
Growth
Impact Impact Growth
Three Months
Ended
Consolidated net sales Consumable $ 1,064,098 $ 1,059,838
0.4 % (2.1 )% — % 2.5 % Equipment and software 249,047 248,779 0.1
% 0.2 % — % (0.1 )% Other 84,273 92,236 (8.6 )% (0.7
)% — % (7.9 )% Total $ 1,397,418 $ 1,400,853 (0.2 )% (1.6 )% — %
1.4 % Dental Consumable $ 325,181 $ 333,835 (2.6 )% 0.2 % —
% (2.8 )% Equipment and software 230,431 232,334 (0.8 )% 0.2 % — %
(1.0 )% Other 70,731 71,482 (1.1 )% 0.2 % — % (1.3 )%
Total $ 626,343 $ 637,651 (1.8 )% 0.2 % — % (2.0 )% Animal
Health Consumable $ 738,917 $ 726,003 1.8 % (3.2 )% — % 5.0 %
Equipment and software 18,616 16,445 13.2 % (0.2 )% — % 13.4 %
Other 5,044 7,265 (30.6 )% (10.9 )% — % (19.7 )%
Total $ 762,577 $ 749,713 1.7 % (3.2 )% — % 4.9 % Corporate
Other $ 8,498 $ 13,489 (37.0 )% — % — % (37.0 )% Total $ 8,498 $
13,489 (37.0 )% — % — % (37.0 )%
Nine Months
Ended
Consolidated net sales Consumable $ 3,252,551 $ 3,042,634
6.9 % (2.2 )% 6.4 % 2.7 % Equipment and software 627,187 610,071
2.8 % — % — % 2.8 % Other 268,357 280,228 (4.2 )%
(0.8 )% (0.1 )% (3.3 )% Total $ 4,148,095 $ 3,932,933 5.5 % (1.8 )%
4.9 % 2.4 % Dental Consumable $ 982,366 $ 1,024,323 (4.1 )%
(0.1 )% — % (4.0 )% Equipment and software 586,375 572,771 2.4 % —
% — % 2.4 % Other 214,170 216,996 (1.3 )% — % — %
(1.3 )% Total $ 1,782,911 $ 1,814,090 (1.7 )% — % — % (1.7 )%
Animal Health Consumable $ 2,270,185 $ 2,018,311 12.5 % (3.3
)% 9.6 % 6.2 % Equipment and software 40,812 37,300 9.4 % (0.2 )% —
% 9.6 % Other 21,357 25,852 (17.4 )% (8.1 )% (0.7 )%
(8.6 )% Total $ 2,332,354 $ 2,081,463 12.1 % (3.3 )% 9.3 % 6.1 %
Corporate Other $ 32,830 $ 37,380 (12.2 )% — % — % (12.2 )%
Total $ 32,830 $ 37,380 (12.2 )% — % — % (12.2 )%
PATTERSON COMPANIES, INC. OPERATING INCOME BY SEGMENT
(In thousands) (Unaudited)
Three Months Ended
Nine Months Ended January 28, January 30,
January 28, January 30, 2017 2016
2017 2016 Operating income (loss) Dental $
40,018 $ 82,108 $ 177,356 $ 223,454 Animal Health 23,777 25,959
60,460 64,108 Corporate (17,241 ) (12,338 )
(46,043 ) (46,193 ) Total $ 46,554 $ 95,729 $
191,773 $ 241,369
PATTERSON
COMPANIES, INC. RECONCILIATION OF GAAP TO NON-GAAP
MEASURES (Dollars in thousands, except per share
amounts) (Unaudited)
For the three months ended January 28, 2017
GAAP Transaction-related costs Deal
amortization Intangible asset impairment Integration
and business restructuring expenses Accelerated debt
issuance costs Tax impact of cash repatriation
Non-GAAP Operating income from continuing operations $
46,554 $ 236 $ 9,951 $ 36,312 $ 625 $ — $ — $ 93,678 Other expense,
net (10,406 ) — — — — —
— (10,406 ) Income from continuing operations
before taxes 36,148 236 9,951 36,312 625 — — 83,272 Income tax
expense 8,379 89 3,480 13,263
236 — 2,406 27,853 Net
income from continuing operations $ 27,769 $ 147 $ 6,471 $
23,049 $ 389 $ — $ (2,406 ) $ 55,419
Diluted EPS from continuing
operations* $ 0.29 $ — $ 0.07 $ 0.24 $ — $ — $ (0.03 ) $
0.58 Consolidated operating income as a % of sales
3.3 % 6.7 % Effective tax rate 23.2 % 33.4 %
For
the three months ended January 30, 2016 GAAP
Transaction-related costs Deal amortization
Intangible asset impairment Integration and business
restructuring expenses Accelerated debt issuance costs
Tax impact of cash repatriation Non-GAAP Operating
income from continuing operations $ 95,729 $ 44 $ 10,793 $ — $
1,613 $ — $ — $ 108,179 Other expense, net (9,804 ) —
— — — — — (9,804 )
Income from continuing operations before taxes 85,925 44 10,793 —
1,613 — — 98,375 Income tax expense 28,735 16
3,872 — 611 — —
33,234 Net income from continuing operations $ 57,190
$ 28 $ 6,921 $ — $ 1,002 $ — $ — $ 65,141
Diluted EPS from
continuing operations* $ 0.60 $ — $ 0.07 $ — $ 0.01 $ — $ —
$ 0.68 Consolidated operating income as a % of
sales 6.8 % 7.7 % Effective tax rate 33.4 % 33.8 %
For the nine months ended January 28, 2017 GAAP
Transaction-related costs Deal amortization
Intangible asset impairment Integration and business
restructuring expenses Accelerated debt issuance costs
Tax impact of cash repatriation Non-GAAP Operating
income from continuing operations $ 191,773 $ 1,479 $ 30,212 $
36,312 $ 6,304 $ — $ — $ 266,080 Other expense, net (26,679
) — — — — — —
(26,679 ) Income from continuing operations before taxes
165,094 1,479 30,212 36,312 6,304 — — 239,401 Income tax expense
52,663 558 10,394 13,263
2,383 — 2,406 81,667 Net income
from continuing operations $ 112,431 $ 921 $ 19,818 $ 23,049
$ 3,921 $ — $ (2,406 ) $ 157,734
Diluted EPS from continuing operations*
$ 1.17 $ 0.01 $ 0.21 $ 0.24 $ 0.04 $ — $ (0.03 ) $ 1.64
Consolidated operating income as a % of sales 4.6 %
6.4 % Effective tax rate 31.9 % 34.1 %
For the
nine months ended January 30, 2016 GAAP
Transaction-related costs Deal amortization
Intangible asset impairment Integration and business
restructuring expenses Accelerated debt issuance costs
Tax impact of cash repatriation Non-GAAP Operating
income from continuing operations $ 241,369 $ 13,132 $ 28,689 $ — $
5,196 $ — $ — $ 288,386 Other expense, net (37,477 )
— — — — 5,153 —
(32,324 ) Income from continuing operations before taxes 203,892
13,132 28,689 — 5,196 5,153 — 256,062 Income tax expense
83,828 3,125 10,182 — 1,965
1,948 (12,300 ) 88,748 Net income from
continuing operations $ 120,064 $ 10,007 $ 18,507 $ — $
3,231 $ 3,205 $ 12,300 $ 167,314
Diluted EPS from continuing
operations* $ 1.22 $ 0.10 $ 0.19 $ — $ 0.03 $ 0.03 $ 0.12
$ 1.70 Consolidated operating income as a % of
sales 6.1 % 7.3 % Effective tax rate 41.1 % 34.7 % * May not
sum due to rounding
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170223005351/en/
Patterson Companies, Inc.Ann B. Gugino,
651-686-1600Executive Vice President & CFOorJohn M. Wright,
651-686-1364Vice President, Investor Relations
Patterson Companies (NASDAQ:PDCO)
Historical Stock Chart
From Apr 2024 to May 2024
Patterson Companies (NASDAQ:PDCO)
Historical Stock Chart
From May 2023 to May 2024